Scarica l'app Stockscreener
2.42
0.41%
0.010
Dopo l'orario di chiusura:
2.43
0.01
+0.41%
Lipella Pharmaceuticals Inc Borsa (LIPO) Ultime notizie
Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN
Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire
Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan
Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance
LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com
Lipella Pharmaceuticals Inc (LIPO) Quarterly 10-Q Report - Quartzy
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipella issued patent by USPTO for liposomal drug delivery platform - TipRanks
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform - The Manila Times
Lipella Pharmaceuticals Secures Extended Market Exclusivity - GlobeNewswire
Lipella Pharma Secures Key Patent for Liposomal Platform, Extends Drug Pipeline Protection to 2035 | LIPO Stock News - StockTitan
China chip index nears 3-year high as TSMC order fuels self-reliance bets - Investing.com
Cathay general bancorp vice chairman sells $2.11 million in stock - Investing.com
Contrasting Wellness Center USA (OTCMKTS:WCUI) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Lipella Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com Australia
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - citybiz
Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com
Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN
Lipella Pharmaceuticals announces 1-for-8 reverse stock split By Investing.com - Investing.com UK
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Ocugen Inc (OCGN) rating initates by Maxim Group - Knox Daily
Potential Price Increase for First Advantage Corp. (FA) After Recent Insider Activity - Knox Daily
Lipella Pharmaceuticals Inc (LIPO) Becoming More Attractive for Investors - Knox Daily
Recent Insider Activity Suggests Potential Gains for KE Holdings Inc ADR (BEKE) - Knox Daily
Lipella Pharmaceuticals Inc [LIPO] is -57.84% lower this YTD. Is it still time to buy? - The DBT News
Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com
Huge semiconductor deal has eyes on this tech co 👀 - RagingBull
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - GlobeNewswire
Interstitial Cystitis Market Size is Set for Rapid Growth as - openPR
Sky Quarry Announces Closing of Public Offering of $6.7 Million - The Manila Times
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Expion360 Inc’s latest rating changes from various analysts - Knox Daily
Insider Buying: Kaufman Jonathan H, Lipella Pharmaceuticals Inc [LIPO] insider invested 10,000 shares - Knox Daily
The time has not yet come to remove your chips from the table: Lipella Pharmaceuticals Inc (LIPO) - SETE News
Lipella Pharmaceuticals Inc Inc. (LIPO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - Morningstar
Lipella reports positive phase 2a trial results for OLP treatment - Investing.com
Lipella Pharmaceuticals Reports Encouraging Early - GlobeNewswire
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus - StockTitan
A year in review: Lipella Pharmaceuticals Inc (LIPO)’s performance in the last year - US Post News
Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex
Lipella stock soars 200% on Phase 2 study initiation - MSN
Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Benzinga
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):